Back to top
more

BioNTech (BNTX)

(Delayed Data from NSDQ)

$88.09 USD

88.09
281,676

-0.40 (-0.45%)

Updated Apr 24, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

BioNTech SE Sponsored ADR (BNTX) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, BioNTech SE Sponsored ADR (BNTX) closed at $124.57, marking a +1.63% move from the previous day.

Wynn Resorts and BioNTech have been highlighted as Zacks Bull and Bear of the Day

Wynn Resorts and BioNTech have been highlighted as Zacks Bull and Bear of the Day.

Andrew Rocco headshot

Bear of the Day: BioNTech (BNTX)

BNTX is ranked a lowly 5 for a reason. Earnings have peaked, COVID hysteria has subsided, and the technical picture is lagging.

Sarepta Therapeutics (SRPT) Soars 7.1%: Is Further Upside Left in the Stock?

Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

BioNTech SE Sponsored ADR (BNTX) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, BioNTech SE Sponsored ADR (BNTX) closed at $132.08, marking a +1.88% move from the previous day.

Pfizer (PFE) Gets FDA Nod for Bivalent COVID Jab in Infants

Pfizer (PFE) and partner BioNTech receive FDA label expansion to use their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as a single booster dose in young children under five years.

Deciphera Pharmaceuticals, Inc. (DCPH) Soars 10.3%: Is Further Upside Left in the Stock?

Deciphera Pharmaceuticals, Inc. (DCPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

BioNTech SE Sponsored ADR (BNTX) Gains As Market Dips: What You Should Know

BioNTech SE Sponsored ADR (BNTX) closed the most recent trading day at $129.77, moving +1.82% from the previous trading session.

BioNTech (BNTX) to Report Q4 Earnings: What's in the Cards?

BioNTech's (BNTX) fourth-quarter COVID-19 vaccine sales are likely to have declined with the pandemic largely in control. Updates on the company's booster dose authorization status and pipeline will be in focus.

BioNTech SE Sponsored ADR (BNTX) Outpaces Stock Market Gains: What You Should Know

BioNTech SE Sponsored ADR (BNTX) closed at $131.54 in the latest trading session, marking a +0.59% move from the prior day.

BioNTech SE Sponsored ADR (BNTX) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, BioNTech SE Sponsored ADR (BNTX) closed at $130.86, marking a -1.84% move from the previous day.

BioNTech SE Sponsored ADR (BNTX) Stock Moves -0.79%: What You Should Know

BioNTech SE Sponsored ADR (BNTX) closed at $137.53 in the latest trading session, marking a -0.79% move from the prior day.

BioNTech SE Sponsored ADR (BNTX) Gains As Market Dips: What You Should Know

BioNTech SE Sponsored ADR (BNTX) closed the most recent trading day at $143.92, moving +0.64% from the previous trading session.

BioNTech SE Sponsored ADR (BNTX) Stock Moves -0.68%: What You Should Know

In the latest trading session, BioNTech SE Sponsored ADR (BNTX) closed at $141.15, marking a -0.68% move from the previous day.

Implied Volatility Surging for BioNTech (BNTX) Stock Options

Investors need to pay close attention to BioNTech (BNTX) stock based on the movements in the options market lately.

BioNTech SE Sponsored ADR (BNTX) Gains But Lags Market: What You Should Know

BioNTech SE Sponsored ADR (BNTX) closed the most recent trading day at $144.40, moving +0.94% from the previous trading session.

Pfizer (PFE) Q4 Earnings Top, 2023 View Disappoints, Stock Down

Pfizer (PFE) beats estimates for Q4 earnings and sales. Its 2023 financial outlook falls short of expectations. Stock down in pre-market trading.

The Zacks Analyst Blog Highlights Pfizer/BioNTech, Moderna and Novavax

Pfizer/BioNTech, Moderna and Novavax are included in this Analyst Blog.

Novavax (NVAX) COVID Jab Aids Growth, Overdependence a Challenge (revised)

Despite being one of the few authorized COVID-19 vaccine makers in the United States, Novavax's (NVAX) vaccine struggles for market share.

FDA Panel Endorses Simplification of COVID-19 Vaccine Strategy

An FDA advisory committee unanimously votes in favor of using the same COVID-19 vaccine strain composition for primary series and booster doses.

Can Pfizer (PFE) Beat Expectations This Earnings Season?

Higher alliance revenues from Eliquis, higher sales of Prevnar vaccines and drugs like Vyndaqel/Vyndamax are likely to have contributed to Pfizer's (PFE) sales growth in Q4.

Novavax (NVAX) COVID Jab Aids Growth, Overdependence A Woe

Despite being one of the few authorized COVID-19 vaccine makers in the United States, Novavax's (NVAX) vaccine struggles for market share.

Novavax (NVAX) Gets Nod for COVID-19 Booster Jab in South Korea

Novavax's (NVAX) COVID-19 vaccine gets approval in South Korea as a booster dose in adults 18 years and older.

Novavax (NVAX) Names John Jacobs as New CEO, Shares Rise

Novavax (NVAX) appoints John C. Jacobs as its new president and chief executive officer, effective Jan 23, 2023.